Results of semaglutide in patients older than 70 years, a real-world study of efficacy and safety - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37337740/
In routine clinical practice in Spain, the use of semaglutide once a week was associated with statistically significant and clinically relevant improvements in HbA 1c and body weight in adults...
Conclusions: In routine clinical practice in Spain, the use of semaglutide once a week was associated with statistically significant and clinically relevant improvements in HbA<inf>1c</inf> and body weight in adults aged over 70 years with T2DM, without notable adverse effects, which supports real-world use.
Share
GLP-1 agonists for people living with HIV and obesity, is there a potential? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37340561/
Theoretical considerations and a few available clinical observations support semaglutide and liraglutide prescription in people with HIV, with, thus far, no indications of concern regarding efficacy, safety or pharmacological interactions...
Conclusion: Theoretical considerations and a few available clinical observations support semaglutide and liraglutide prescription in people with HIV, with, thus far, no indications of concern regarding efficacy, safety or pharmacological interactions with ARVs.
Share
Perspectives in weight control in diabetes - BI 456906 - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37330144/
Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved treatments for Type 2 diabetes mellitus, with liraglutide and semaglutide also approved for the treatment of obesity. The natural gut hormone oxyntomodulin is...
Conclusions/Relevance: These data highlight the potential of dual GCGR/GLP-1R agonism for reducing glycated haemoglobin and body weight in patients with Type 2 diabetes mellitus, and for greater therapeutic efficacy compared with GLP-1R agonism alone.
Share
Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37313232/
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have gained traction for the management of type 2 diabetes and obesity. Unlike several classes of antidiabetic medications that contribute to weight gain, GLP-1RAs not...
Conclusions/Relevance: The outcomes of paediatric trials evaluating liraglutide, exenatide, semaglutide and dulaglutide in paediatric type 2 diabetes and obesity will be closely examined, including differences compared with adult studies. Finally, potential barriers and strategies to expanding GLP-1RA access in adolescents will be discussed....
Share
Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis - International Journal of Obesity
Source : https://www.nature.com/articles/s41366-023-01321-5
Recent studies suggest that tirzepatide, a dual glucose-dependent insulinotropic-peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA), has significant weight loss effects. This systematic review and meta-analysis aims to assess...
Conclusion: Tirzepatide has significant potential as a weight loss drug in patients with overweight and obesity, with little increase in AEs compared to other weight loss drugs. With its ability to concurrently target multiple aspects of metabolic syndrome, it should be considered as the next helm of weight loss therapies.
Share